Robert F. Kennedy Jr., President Trump's nominee to lead HHS, spoke highly of GLP-1 drugs at a Senate confirmation hearing ...
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.